DOSMALFATE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C28H24O39S8.14Al.35HO
Molecular Weight	2213.985
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	-1

SHOW SMILES / InChI

Structure Search

SMILES

[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].COC1=CC=C(C=C1OS([O-])(=O)=O)C2=CC(=O)C3=C(O2)C=C(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](OS([O-])(=O)=O)[C@@H](OS([O-])(=O)=O)[C@H]5OS([O-])(=O)=O)[C@@H](OS([O-])(=O)=O)[C@H](OS([O-])(=O)=O)[C@H]4OS([O-])(=O)=O)C=C3OS([O-])(=O)=O

InChI

InChIKey=RIIQJLBJDMMSSK-RHFFRRHRSA-A

InChI=1S/C28H32O39S8.14Al.35H2O/c1-10-21(62-70(36,37)38)23(64-72(42,43)44)25(66-74(48,49)50)27(56-10)55-9-19-22(63-71(39,40)41)24(65-73(45,46)47)26(67-75(51,52)53)28(59-19)57-12-6-17-20(18(7-12)61-69(33,34)35)13(29)8-15(58-17)11-3-4-14(54-2)16(5-11)60-68(30,31)32;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h3-8,10,19,21-28H,9H2,1-2H3,(H,30,31,32)(H,33,34,35)(H,36,37,38)(H,39,40,41)(H,42,43,44)(H,45,46,47)(H,48,49,50)(H,51,52,53);;;;;;;;;;;;;;;35*1H2/q;14*+3;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/p-43/t10-,19+,21-,22+,23+,24-,25+,26+,27+,28+;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/m0................................................./s1

HIDE SMILES / InChI

Description
Sources: https://www.researchgate.net/profile/Luis_Labeaga/publication/282324623_Pharmacological_profile_of_Dosmalfate/links/561cd52c08ae6d17308d29f0.pdf | http://prospecto-medicamento.com/4476-diotulfaes-ampollas-bebibles-30-ampollas.html

Dosmalfate (diosmin heptakis) is a cytoprotective agent of flavonoid nature. It acts as a non-systemic antiulcer agent lacking antisecretory activity, capable of constituting a complex with the pepsin protein substrate or with pepsin itself. The drug was marketed in Spain under the name Diotulfase (among the others) for the treatment of NSIAD-induced ulcer, however, it is no longer available.

CNS Activity

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
NSAID-induced ulcer 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12559383	Curative		Approved 8429	DIOTULFAES Approved Use Prevention and treatment of gastroduodenal injuries induced by chronic treatments with non-steroidal anti-inflammatory drugs.

PubMed

Title	Date	PubMed
A new flavonoid derivative, dosmalfate, attenuates the development of dextran sulphate sodium-induced colitis in mice.	2003 Dec	14636824
Effects of dosmalfate, a new cytoprotective agent, on acute and chronic trinitrobenzene sulphonic acid-induced colitis in rats.	2003 Jan 24	12559383

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage is 3 g per day, divided into two doses, preferably with an empty stomach.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

DOSMALFATE

Official Name

English

(.MU.(SUB 7)-((DIOSMIN HEPTASULFATO)(7-)))TETRACONTAHYDROXYTETRADECAALUMINUM

Common Name

English

(.MU.(SUB 7)-((DIOSMIN HEPTASULFATO)(7-)))TETRACONTAHYDROXYTETRADECAALUMINIUM

Common Name

English

dosmalfate [INN]

Common Name

English

DOSMALFATE [MART.]

Common Name

English

Dosmalfate [WHO-DD]

Common Name

English

DOSMALFATE [MI]

Common Name

English

Code System Code Type Description

MERCK INDEX

m4746